Riferimento farmaci
Venetoclax
Venetoclax is a medicine in the class miscellaneous. It is used for chronic lymphocytic leukemia.
- Classe del farmaco: Miscellaneous
- Indicato per: chronic lymphocytic leukemia
Ultimo aggiornamento Fonti: US FDA label
Per operatori sanitari — solo a scopo di riferimento. Questa pagina è una sintesi breve, non è un parere medico e non sostituisce il RCP ufficiale né il giudizio clinico. Verificare sempre prima di prescrivere o dispensare.
Il contenuto clinico di questa pagina è disponibile solo in inglese.
In breve
- Classe del farmaco
- Miscellaneous
- Codice ATC
- L01XX52
- Forme farmaceutiche comuni
- compressa
- Dosaggi comuni
- 10 mg
- Interazioni note
- 68 (Controindicata: 5 · Maggiore: 37 · Moderata: 23 · Minore: 3)
- Nomi commerciali
- 3
- Paesi e mercati
- 3
Per cosa si usa
Come agisce
Selective, orally bioavailable small-molecule inhibitor of BCL-2, an anti-apoptotic protein. It binds BCL-2 directly, displacing pro-apoptotic proteins like BIM, which restores apoptosis through mitochondrial outer membrane permeabilization and caspase activation.
Dose abituale nell'adulto (sintesi del foglio illustrativo)
CLL/SLL: 5-week ramp-up orally once daily (Week 1 20 mg, Week 2 50 mg, Week 3 100 mg, Week 4 200 mg), then 400 mg once daily from Week 5 and beyond
Gravidanza e allattamento
- Gravidanza
- Unsafe May cause fetal harm: in mice it caused embryo loss and lower fetal weight at about 1.2 times human exposure; no malformations; no human data. Avoid; use effective contraception during treatment and for 30 days after the last dose.
- Allattamento
- Unsafe No human milk data; it passes into rat milk. Because of possible serious infant reactions, do not breastfeed during treatment and for 1 week after the last dose. LactMed: most sources advise against breastfeeding during cancer drug therapy.
Effetti indesiderati segnalati
- Neutropenia
- Thrombocytopenia
- Anemia
- Diarrhea
- Nausea
- Fatigue
Controindicazioni
- Concomitant use with strong CYP3A inhibitors at initiation and during the ramp-up phase in patients with CLL/SLL, due to increased TLS risk
Chi deve prestare attenzione
- Tumor lysis syndrome, including fatal events and renal failure requiring dialysis; assess risk, give hydration and anti-hyperuricemics, and monitor blood chemistries
- Neutropenia: monitor complete blood counts throughout treatment and consider supportive measures
- Fatal and serious infections such as pneumonia and sepsis; withhold for Grade 3 and 4 infection until resolution
Informare il farmacista o il medico di gravidanza o allattamento, malattie renali o epatiche, allergie e di ogni altro farmaco o integratore assunto.
Interazioni principali (68)
- Clarithromycin + Venetoclax Contraindicated
- Itraconazole + Venetoclax Contraindicated
- Ketoconazole + Venetoclax Contraindicated
- Posaconazole + Venetoclax Contraindicated
- Venetoclax + Voriconazole Contraindicated
- Amiodarone + Venetoclax Major
- Apalutamide + Venetoclax Major
- Aprepitant + Venetoclax Major
- Armodafinil + Venetoclax Major
- Bosentan + Venetoclax Major
Per gli utenti Pro+
Sblocca la pagina completa
Crei un account e avvii una prova di Pro+ per aprire la monografia completa di Venetoclax: dosi, gravidanza e allattamento, effetti indesiderati, avvertenze e tutte le interazioni.
- Dosing by age, kidney and liver function, and further dose lines
- Renal and hepatic dose adjustments
- How to give it
- Pharmacokinetics
- Patient counselling points
- Food interactions
Provi Pro+ gratis per 14 giorni sul web. Nessuna carta.
Domande frequenti
What is Venetoclax used for?
Venetoclax is a medicine in the class miscellaneous. It is used for Chronic lymphocytic leukemia, Leukemia.
What side effects have been reported with Venetoclax?
Neutropenia, Thrombocytopenia, Anemia, Diarrhea, Nausea, Fatigue.
Can Venetoclax be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. May cause fetal harm: in mice it caused embryo loss and lower fetal weight at about 1.2 times human exposure; no malformations; no human data. Avoid; use effective contraception during treatment and for 30 days after the last dose. Breastfeeding: Unsafe. No human milk data; it passes into rat milk. Because of possible serious infant reactions, do not breastfeed during treatment and for 1 week after the last dose. LactMed: most sources advise against breastfeeding during cancer drug therapy.
What does Venetoclax interact with?
MediHelp lists 68 known interactions for Venetoclax. Contraindicated: 5 · Major: 37 · Moderate: 23 · Minor: 3. The most serious include Clarithromycin, Itraconazole, Ketoconazole.
Monografie complete, posologie e verifica delle interazioni nell'app MediHelp
Apra il riferimento completo, verifichi le interazioni tra più farmaci e usi gli strumenti di posologia nell'app MediHelp.
